Nomir Medical Technologies, known for innovative laser therapies and novel photobiology, has recently declared that its milestone pivotal onychomycosis trial provided a new data, which has been published once more in the peer-reviewed Journal of the American Podiatric Medical Association (JAPMA).
Photo of Noveon Laser (Photo: Business Wire)
The report on the new paper is based on a 270 day onychomycosis clinical trial. It promotes the application of the Noveon lasers as a powerful therapeutic treatment.
This newly released paper is a subsequent follow-up of the first JAPMA paper on Noveon-based laser treatments that can cure podiatric infectious disease. The second paper is based on the 180 day human clinical trial for the Noveon-based treatment for onychomycosis. Marking third in the series, this paper represents Nomir’s Noveon-based peer reviewed articles published in JAPMA and results from an extended clinical trial of 270 days.
The major observations presented in the recently published paper are as follows:
- It takes nine months for clear nail improvement. In the study, around 85% of the treated toenails resulted in clear linear nail improvement at Day 180, with P level measuring 0.0015. At Day 270, despite the termination of laser treatments 150 days earlier, showed further improvements up to 35%.
- In spite of an extended trial period of 270 days, adverse side effects were not seen in any of the patients under study.
- Nail fungus infection rates are slowly decreased at day 270, showing negative mycology.
- Some patients demonstrated a complete cure. A majority of patients achieved clinical cure at day 270 and showed completely normal appearance than at day 180.